Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine phosphate 3Doxorubicin 3Cytarabine 3venetoclax 2Vincristine 2Mycophenolic Acid 2Filgrastim 2Dexamethasone 2Cyclophosphamide 2Calcium Dobesilate 2pegaspargase 1obatoclax 1lirilumab 1liposomal doxorubicin 1ixazomib 1fludarabine 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1Whole-Body Irradiation 1Vorinostat 1Tetradecanoylphorbol Acetate 1Tacrolimus 1Sunitinib 1Razoxane 1Radiotherapy 1Platelet Transfusion 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Moxifloxacin 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Biphenotypic, Acute × lirilumab × Clear all
NCT02399917 2019-09-24

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
36 enrolled 14 charts
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡